REGULATORY
LDP’s Pharma Study Group to Form Panel for Patch Medications, Proposal Due Out This Autumn
The ruling Liberal Democratic Party’s (LDP) study group on pharmaceutical policies will launch a new panel dedicated to patch medications, which will discuss ways to defend their health coverage and appropriate pricing that would ensure their stable supplies, informed sources…
To read the full story
Related Article
- LDP’s Patch Panel Boots Up with Bigwig Noda as Chairman
June 28, 2018
REGULATORY
- MHLW Issues Q&A on Conditional Approval System
May 1, 2026
- Panel Backs Proposal to Allow Antibody Drugs Like Beyfortus in NIP
May 1, 2026
- METI Clarifies Naphtha Comments, Reaffirms Medical Priority
April 30, 2026
- Japan Minister Rules Out Full Self-Pay for OTC-Like Drugs
April 30, 2026
- Govt’s Bio-WG Wraps Up Biopharma Investment Roadmap Draft
April 30, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





